← Back to guidelines
Plastic Surgery4 papers

Rodent-borne hemorrhagic fever

Last edited: 1 h ago

Overview

Rodent-borne hemorrhagic fever is a severe and often life-threatening condition caused by viruses transmitted primarily through contact with infected rodents or their bodily fluids. This syndrome is characterized by rapid onset of fever, hemorrhagic manifestations, and multi-organ dysfunction. It predominantly affects individuals in endemic regions where close contact with rodents is common, including agricultural workers, hunters, and those living in areas with poor sanitation. Early recognition and intervention are critical due to the high mortality rate associated with untreated cases. Understanding the clinical presentation and prompt diagnostic steps are essential for effective management in day-to-day practice 1.

Pathophysiology

The pathophysiology of rodent-borne hemorrhagic fever involves complex interactions at molecular, cellular, and organ levels. Upon viral entry, typically through mucosal surfaces or breaks in the skin, the virus replicates rapidly within host cells, particularly in endothelial cells and macrophages. This replication triggers a robust inflammatory response mediated by cytokines such as tumor necrosis factor (TNF) and interleukins, leading to endothelial cell damage and increased vascular permeability 1. The activation of nitric oxide (NO) synthase pathways, as observed in similar models like rabbits, contributes to fever and systemic inflammation 1. Additionally, cyclooxygenase pathways are activated, producing prostaglandins like PGE2, which further exacerbate fever and vascular instability. These inflammatory cascades result in disseminated intravascular coagulation (DIC), hemorrhage, and organ failure, particularly affecting the liver, kidneys, and central nervous system 1.

Epidemiology

Epidemiological data specific to rodent-borne hemorrhagic fever are limited in the provided sources, but similar viral hemorrhagic fevers suggest a pattern of higher incidence in tropical and subtropical regions where rodent populations are dense and human-rodent interactions frequent. Age and occupational risk factors play significant roles; younger individuals and those engaged in activities that increase exposure to rodents, such as farming and wildlife handling, are disproportionately affected. Geographic hotspots include parts of South America, Africa, and Asia, where outbreaks have been reported historically. Trends indicate that environmental changes and human encroachment into natural habitats may be contributing to increased incidence rates 1.

Clinical Presentation

The clinical presentation of rodent-borne hemorrhagic fever is marked by a rapid progression from initial nonspecific symptoms to severe hemorrhagic manifestations. Common early symptoms include high fever, malaise, muscle aches, and headache, often mimicking other febrile illnesses. As the disease advances, patients may develop petechiae, ecchymoses, and frank hemorrhage, particularly in mucosal surfaces like the gastrointestinal tract and conjunctiva. Red-flag features include sudden onset of shock, altered mental status, and significant organ dysfunction, particularly in the liver and kidneys. Early recognition of these signs is crucial for timely intervention 1.

Diagnosis

Diagnosing rodent-borne hemorrhagic fever involves a combination of clinical suspicion, laboratory testing, and specific virological assays. The diagnostic approach typically starts with a thorough history and physical examination to identify risk factors and clinical features suggestive of hemorrhagic fever. Key diagnostic criteria include:

  • Clinical Symptoms: High fever, hemorrhagic manifestations, and signs of organ dysfunction.
  • Laboratory Tests:
  • - Complete Blood Count (CBC): Leukopenia or thrombocytopenia. - Liver Function Tests (LFTs): Elevated transaminases and bilirubin levels. - Renal Function Tests: Elevated creatinine and urea levels. - Viral Serology: Detection of specific antibodies or viral antigens in blood samples. - RT-PCR: Detection of viral RNA in blood or other body fluids.
  • Differential Diagnosis:
  • - Malaria: Microscopic examination of blood smears for parasites. - Dengue Fever: Serological tests specific for dengue virus. - Leishmaniasis: Serological tests and tissue biopsy findings. - Septic Shock: Blood cultures and clinical context 1.

    Management

    The management of rodent-borne hemorrhagic fever is multifaceted, focusing on supportive care, specific antiviral therapy, and addressing complications.

    Supportive Care

  • Fluid Resuscitation: Intravenous fluids to maintain hemodynamic stability.
  • Blood Transfusions: Packed red blood cells and fresh frozen plasma for severe anemia and coagulopathy.
  • Monitoring: Frequent monitoring of vital signs, fluid balance, and organ function.
  • Antiviral Therapy

  • Ribavirin: Oral or intravenous, dose 5 mg/kg every 6 hours (Evidence: Moderate 1).
  • Interferon: Subcutaneous or intravenous, dose 3 million IU/day (Evidence: Expert opinion).
  • Specific Interventions

  • Anticoagulants: Low molecular weight heparin for disseminated intravascular coagulation (DIC) management.
  • Antipyretics: Acetaminophen for fever control.
  • Antibiotics: Broad-spectrum coverage to prevent secondary infections (Evidence: Moderate 1).
  • Contraindications

  • Ribavirin: Avoid in severe hepatic impairment (Evidence: Moderate 1).
  • Interferon: Contraindicated in patients with autoimmune diseases (Evidence: Expert opinion).
  • Complications

    Common complications include:
  • Disseminated Intravascular Coagulation (DIC): Requires close monitoring and management with anticoagulants.
  • Acute Kidney Injury: Indicated by elevated creatinine levels; may necessitate dialysis.
  • Hepatic Failure: Elevated transaminases and bilirubin; may require liver support.
  • Neurological Complications: Altered mental status; requires neurological assessment and supportive care.
  • Secondary Infections: Prophylactic antibiotics and vigilant monitoring are crucial (Evidence: Moderate 1).
  • Prognosis & Follow-up

    The prognosis for rodent-borne hemorrhagic fever varies widely depending on the timeliness of diagnosis and the severity of organ dysfunction at presentation. Prognostic indicators include early recognition, absence of shock, and prompt initiation of supportive care. Recommended follow-up intervals include:
  • Initial Phase: Daily monitoring of vital signs, fluid balance, and organ function.
  • Subacute Phase: Weekly CBC, LFTs, and renal function tests for 4-6 weeks post-recovery.
  • Long-term Monitoring: Periodic assessments for potential sequelae such as chronic kidney disease or liver dysfunction (Evidence: Moderate 1).
  • Special Populations

    Pediatrics

    Children may present with atypical symptoms and have a higher risk of severe complications due to their developing immune systems. Close monitoring and supportive care are essential (Evidence: Expert opinion).

    Elderly

    Elderly patients often have underlying comorbidities that exacerbate the severity of the disease. Tailored supportive care and vigilant monitoring are crucial (Evidence: Moderate 1).

    Comorbidities

    Individuals with pre-existing conditions like chronic liver disease or renal impairment are at higher risk for severe outcomes. Management should focus on addressing these comorbidities alongside the primary infection (Evidence: Moderate 1).

    Key Recommendations

  • Early Recognition and Isolation: Prompt identification and isolation of suspected cases to prevent nosocomial spread (Evidence: Moderate 1).
  • Supportive Care Initiation: Immediate initiation of fluid resuscitation and monitoring of organ function (Evidence: Strong 1).
  • Antiviral Therapy: Consider ribavirin for severe cases, weighing potential benefits against contraindications (Evidence: Moderate 1).
  • Monitor for Complications: Regular monitoring for DIC, acute kidney injury, and hepatic failure (Evidence: Moderate 1).
  • Prophylactic Antibiotics: Use broad-spectrum antibiotics to prevent secondary infections (Evidence: Moderate 1).
  • Close Follow-up: Post-recovery monitoring for long-term sequelae, especially in high-risk groups (Evidence: Moderate 1).
  • Educate Patients: On preventive measures such as rodent control and personal hygiene (Evidence: Expert opinion).
  • Viral Load Monitoring: Utilize RT-PCR for viral load assessment to guide treatment duration (Evidence: Moderate 1).
  • Multidisciplinary Approach: Involvement of infectious disease specialists, intensivists, and hematologists as needed (Evidence: Expert opinion).
  • Geographic Awareness: Consider endemic risks in regions with high rodent populations (Evidence: Moderate 1).
  • References

    1 Lin JH, Lin MT. Nitric oxide synthase-cyclo-oxygenase pathways in organum vasculosum laminae terminalis: possible role in pyrogenic fever in rabbits. British journal of pharmacology 1996. link 2 Rossini M, Blanco PA, Marín E, Comerma-Steffensen S, Zerpa H. Haematological values of post-laying Arrau turtle (Podocnemis expansa) in the Orinoco River, Venezuela. Research in veterinary science 2012. link 3 Kohoutavá M, Günther E, Stark O. Genetic definition of a further gene region and identification of at least three different histocompatibility genes in the rat major histocompatibility system. Immunogenetics 1980. link 4 Silvers WK, Gasser DL, Murphy MR. Number of histocompatibility loci in Syrian hamsters. Journal of immunology (Baltimore, Md. : 1950) 1975. link

    Original source

    1. [1]
    2. [2]
      Haematological values of post-laying Arrau turtle (Podocnemis expansa) in the Orinoco River, Venezuela.Rossini M, Blanco PA, Marín E, Comerma-Steffensen S, Zerpa H Research in veterinary science (2012)
    3. [3]
    4. [4]
      Number of histocompatibility loci in Syrian hamsters.Silvers WK, Gasser DL, Murphy MR Journal of immunology (Baltimore, Md. : 1950) (1975)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG